Kofed(30 mg+100 mg+1.25 mg)/5 ml

Kofed is a fixed-dose combination of a nasal decongestant (pseudoephedrine), an expectorant (guaiphenasine/guaifenesin), and a first-generation sedating antihistamine (triprolidine). It is indicated for the short-term, symptomatic relief of symptoms associated with the common cold, upper respiratory tract infections, allergic rhinitis, and sinusitis.

Established / labeled uses

• Temporary relief of nasal and sinus congestion due to the common cold, hay fever (allergic rhinitis), or other upper respiratory allergies.
• Relief of sneezing, rhinorrhea (runny nose), and itchy, watery eyes associated with allergy or the common cold.
• To help loosen mucus and thin bronchial secretions, making unproductive coughs more productive, in cough associated with the common cold.

Important limitations

Kofed provides only symptomatic relief; it does not treat the underlying infection or cause of allergy. It is not indicated for chronic or persistent cough (such as occurs with smoking, chronic bronchitis, emphysema, or asthma) or for cough accompanied by excessive phlegm, unless directed by a physician. It is not recommended for use in young children (see Pediatric Use) and is intended for short-term use only (see Duration of Treatment).

Pseudoephedrine + Guaiphenasine + Triprolidine is a fixed-dose combination product. Each dosage unit (tablet, capsule, or a measured volume of oral syrup, depending on the manufacturer's formulation) contains three active ingredients in fixed proportions:

• Pseudoephedrine Hydrochloride — a sympathomimetic nasal decongestant.
• Guaiphenasine (Guaifenesin) — an expectorant.
• Triprolidine Hydrochloride — a first-generation (sedating) H1-antihistamine.

Exact strengths per tablet or per 5 mL of syrup vary by brand and dosage form. Always check the product label/pack insert of the specific brand dispensed for the exact composition, and use the measuring device provided with liquid formulations.

Kofed is an oral combination medicine marketed for the symptomatic relief of common cold and upper respiratory allergy symptoms. It combines three complementary actions in a single dosage form: pseudoephedrine narrows swollen nasal blood vessels to relieve congestion, guaiphenasine (guaifenesin) thins and loosens mucus in the airways to ease coughing up phlegm, and triprolidine blocks histamine to reduce sneezing, runny nose, and itchy, watery eyes.

It is typically available as a tablet or oral syrup and is sold in Bangladesh and other markets as an over-the-counter/pharmacy product for short-term use, though pseudoephedrine-containing products may be subject to purchase restrictions in some jurisdictions because pseudoephedrine is a regulated precursor chemical.

Kofed belongs to a combination therapeutic class comprising a Nasal Decongestant (Sympathomimetic), an Expectorant, and a Sedating (First-generation) Antihistamine — commonly grouped under Cold, Cough & Allergy (Anti-allergic and Respiratory) preparations.

Pharmacodynamics

Pseudoephedrine + Guaiphenasine + Triprolidine combines three active substances with distinct mechanisms:

• Pseudoephedrine is an indirect-acting sympathomimetic amine. It stimulates alpha-adrenergic receptors in the nasal mucosa, producing vasoconstriction that shrinks swollen nasal blood vessels and reduces mucosal edema, relieving nasal and sinus congestion.
• Guaiphenasine (Guaifenesin) is an expectorant that increases the volume and reduces the viscosity of respiratory tract secretions by stimulating the vagal reflex in the gastric mucosa, which reflexively increases bronchial gland secretion. This helps loosen phlegm and makes coughs more productive.
• Triprolidine is a first-generation H1-receptor antagonist (antihistamine) that competitively blocks histamine at H1-receptors, reducing sneezing, rhinorrhea, and itching/watering of the eyes. It also has anticholinergic and CNS-depressant (sedating) properties.

Pharmacokinetics

Pseudoephedrine is well absorbed orally, with onset of decongestant action within 30–60 minutes and a duration of action of roughly 4–6 hours (longer for extended-release forms); it is largely excreted unchanged in urine. Guaiphenasine (guaifenesin) is rapidly absorbed and metabolized in the liver, with a short elimination half-life (around 1 hour). Triprolidine is well absorbed orally, undergoes hepatic metabolism, and has a plasma half-life of approximately 3–6 hours, with clinical antihistaminic effect typically lasting 4–6 hours.

Kofed is administered orally. Tablets/capsules should be swallowed whole with a glass of water; syrup formulations should be measured accurately using the measuring cup/spoon provided (not a household spoon). It may be taken with or without food, although taking it with food may reduce stomach upset. Because triprolidine can cause drowsiness while pseudoephedrine can cause stimulation/insomnia, avoid taking the last dose of the day too close to bedtime unless advised otherwise, and avoid alcohol while taking this medicine.

Kofed has clinically significant interactions with the following:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of stopping an MAOI, can cause a hypertensive crisis due to the pseudoephedrine component (see Contraindications).
• Other sympathomimetics/decongestants (e.g. other cold remedies, appetite suppressants, ADHD stimulants): additive cardiovascular stimulation, increasing risk of hypertension, tachycardia, and arrhythmia.
• Antihypertensive agents (e.g. beta-blockers, methyldopa, other agents that deplete or block sympathetic activity): pseudoephedrine may reduce their antihypertensive effect.
• CNS depressants (alcohol, sedatives, hypnotics, opioids, benzodiazepines, tricyclic antidepressants): additive sedation and psychomotor impairment from the triprolidine component.
• Other anticholinergic drugs: additive anticholinergic effects (dry mouth, blurred vision, urinary retention, constipation) from the triprolidine component.
• Digoxin and other cardiac glycosides: sympathomimetics such as pseudoephedrine may increase the risk of cardiac arrhythmia.

Side effects of Kofed arise from its three components and range from common/mild to rare/serious.

Common

• Drowsiness or sedation (from triprolidine) — may paradoxically coexist with:
• Nervousness, restlessness, insomnia, or excitability (from pseudoephedrine)
• Dry mouth, nose, or throat; blurred vision; thickened bronchial secretions (anticholinergic effects)
• Dizziness, headache
• Nausea, vomiting, stomach upset

Less common

• Palpitations, tachycardia, mild elevation in blood pressure
• Difficulty urinating or urinary retention (especially in men with prostate enlargement)
• Paradoxical excitability, nervousness, or, rarely, hallucinations — particularly in children

Rare / serious

• Cardiac arrhythmia, severe hypertension
• Seizures
• Severe allergic reaction (rash, angioedema, difficulty breathing) — seek emergency care immediately

Pregnancy: Kofed should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Pseudoephedrine has been associated with a possible small increased risk of certain birth defects (e.g. gastroschisis) when used in early pregnancy in some studies, and is generally avoided in the first trimester unless necessary. Data on triprolidine and guaiphenasine (guaifenesin) in pregnancy are limited. A physician should always be consulted before use in pregnancy.

Lactation: Pseudoephedrine and triprolidine are both excreted into breast milk in small amounts. Pseudoephedrine may reduce milk production/supply, and triprolidine may cause sedation, irritability, or feeding difficulty in the nursing infant. Use during breastfeeding is not recommended unless a physician determines the benefit outweighs the risk; if used, the infant should be monitored for unusual drowsiness or irritability.

Use Kofed with caution, and only after consulting a physician or pharmacist, in the following situations:

• Cardiovascular disease: hypertension, coronary artery disease, or arrhythmia — the pseudoephedrine component can raise blood pressure and heart rate.
• Hyperthyroidism and diabetes mellitus: sympathomimetics can worsen these conditions.
• Narrow-angle (angle-closure) glaucoma, symptomatic prostatic hypertrophy (BPH), or urinary retention: the anticholinergic effect of triprolidine can precipitate acute glaucoma or worsen urinary retention.
• Asthma, chronic bronchitis, emphysema, or chronic productive cough: antihistamines can thicken secretions; consult a physician before use.
• CNS depression/sedation: triprolidine causes drowsiness; avoid driving, operating machinery, or other activities requiring mental alertness until the effect on the individual is known, and avoid alcohol or other sedating medicines.
• Regulatory note: because pseudoephedrine is a regulated precursor chemical, this product may be sold as a pharmacy-restricted item with purchase quantity limits and require presenting identification, in accordance with local drug-control regulations.

Use only for short-term symptomatic relief (see Duration of Treatment); stop use and consult a physician if symptoms persist, worsen, or new symptoms (fever, rash, persistent headache) occur.

Overdose of Kofed can be serious, particularly in young children, and may involve any or all of its three components. Possible features include marked CNS stimulation (restlessness, tremor, insomnia, seizures) or, conversely, CNS depression/sedation and respiratory depression; hallucinations; severe hypertension, tachycardia, or cardiac arrhythmia; anticholinergic toxicity (dry flushed skin, dilated pupils, urinary retention, hyperthermia); and, in severe cases, coma.

Suspected overdose is a medical emergency. Seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt unsupervised home treatment; take the product packaging with you to the hospital to assist medical staff.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Elderly: Patients over 60 years are generally more sensitive to the sedative, anticholinergic, and cardiovascular (blood pressure/heart rate) effects of Kofed; a lower starting dose and close monitoring are advised, with particular caution in men with prostatic enlargement.

Renal impairment: Pseudoephedrine is largely renally excreted; dose reduction or avoidance may be needed in significant renal impairment — consult a physician.

Hepatic impairment: Use with caution, as guaiphenasine (guaifenesin) and triprolidine undergo hepatic metabolism; consult a physician for dose adjustment in significant hepatic disease.

Children: See Pediatric Use for age-specific restrictions.

Pregnancy and breastfeeding: See Pregnancy and Lactation.

Kofed is intended for short-term, symptomatic use only. Do not use for more than 7 days for cough/cold/congestion symptoms, or more than 5 days for accompanying fever, without consulting a physician. Persistent or worsening symptoms beyond this period may indicate a condition requiring different treatment (e.g. bacterial infection) and warrant medical evaluation.

Sympathomimetic Nasal Decongestant + Expectorant + First-generation (Sedating) H1-Antihistamine — Cold, Cough and Allergy Combination

Pseudoephedrine + Guaiphenasine + Triprolidine acts through three complementary mechanisms: pseudoephedrine stimulates alpha-adrenergic receptors to constrict dilated nasal blood vessels and relieve congestion; guaiphenasine (guaifenesin) increases respiratory tract fluid secretion to loosen and thin mucus, aiding its expulsion; and triprolidine blocks H1-histamine receptors to suppress sneezing, rhinorrhea, and ocular itching/watering caused by histamine release in allergic and cold-related upper airway inflammation.

C (legacy FDA pregnancy category, applicable to all three components — pseudoephedrine, guaiphenasine/guaifenesin, and triprolidine)

Kofed is not recommended for use in children under 6 years of age. Regulatory and expert bodies (including FDA public health communications and voluntary manufacturer labeling in the United States, largely mirrored in other markets) advise against use of combination over-the-counter cough and cold products, including decongestant-antihistamine-expectorant combinations, in children younger than 4–6 years, because of the risk of serious adverse effects (including, rarely, fatal overdose in infants and toddlers) and a lack of demonstrated benefit in this age group.

For children 6–12 years, use only a reduced, age-appropriate dose as specified on the product label and only under the guidance of a physician or pharmacist, for the shortest duration necessary. Safety and efficacy in children under 6 years have not been established for this fixed combination. Parents/caregivers should watch for paradoxical excitability, unusual drowsiness, or behavioral changes in children using this medicine and seek medical advice if these occur.